RLAY Stock Recent News

Relay Therapeutics to host conference call following AACR presentation Relay Therapeutics to host conference call following AACR presentation

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month, at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET and the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 4:05 p.m. ET.

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of 21.13% and 66.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full year 2022 financial results and corporate highlights after the close of market on Thursday, February 23, 2023. The company will not be conducting a teleconference in conjunction with its financial results press release.

Relay Therapeutics, Inc. discovers drugs using a novel computational approach. There is some proof of concept data.

Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 2:15 p.m. PT. The presentation will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the presentation.

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics' RLY-2608 is the first pan-allosteric PIKCA mutation inhibitor and has shown promise in preclinical studies, including better safety vs. Piqray (competition). Phase 1 dose escalation data for RLY-2608 is expected in the first half of 2023. The product candidate has the potential to be a blockbuster drug.

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.